Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tandem Diabetes Care, Inc. - Common Stock (NQ:TNDM)

21.32 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Tandem Diabetes Care, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Tandem Diabetes Care Stock: A Deep Dive Into Analyst Perspectives (10 Ratings)
Via Benzinga
Tandem Diabetes’s (NASDAQ:TNDM) Q1: Beats On Revenue, Stock Soars
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 22.3% year on year to $234.4 million. The company expects the full... 
Via StockStory
Tandem Diabetes (NASDAQ:TNDM) Posts Better-Than-Expected Sales In Q1, Stock Soars
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 22.3% year on year to $234.4 million. The company expects... 
Via StockStory
Earnings Scheduled For April 30, 2025
Via Benzinga
Insights into Tandem Diabetes Care's Upcoming Earnings
Via Benzinga
The Analyst Verdict: Tandem Diabetes Care In The Eyes Of 4 Experts
Via Benzinga
Earnings Scheduled For February 26, 2025
Via Benzinga
Unveiling 8 Analyst Insights On Tandem Diabetes Care
Via Benzinga
Tandem Diabetes (TNDM) Q1 Earnings Report Preview: What To Look For
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) will be reporting results tomorrow after the bell. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
1 Volatile Stock Worth Your Attention and 2 to Keep Off Your Radar
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced... 
Via StockStory
Q4 Earnings Outperformers: Tandem Diabetes (NASDAQ:TNDM) And The Rest Of The Healthcare Technology Stocks
Let’s dig into the relative performance of Tandem Diabetes (NASDAQ:TNDM) and its peers as we unravel the now-completed Q4 healthcare technology earnings season. 
Via StockStory
2 Beaten-Down Stocks to Avoid in the Tariff-Fueled Correction
Via The Motley Fool
Topics Artificial Intelligence Government World Trade
Exposures Artificial Intelligence Political Tariff
The Analyst Verdict: Tandem Diabetes Care In The Eyes Of 5 Experts
Via Benzinga
Forecasting The Future: 9 Analyst Projections For Tandem Diabetes Care
Via Benzinga
Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry
Trump's 10% global tariff spares pharmaceuticals but impacts medical devices, with diabetes device makers facing the greatest strain. Large biopharma firms remain protected, while medtech companies... 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
3 Reasons to Sell TNDM and 1 Stock to Buy Instead
Shareholders of Tandem Diabetes would probably like to forget the past six months even happened. The stock dropped 54.1% and now trades at $20.22. This was partly driven by its softer quarterly results... 
Via StockStory
3 Healthcare Stocks Walking a Fine Line
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
This H.B. Fuller Company Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
Which stocks are experiencing notable movement on Thursday?
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements. 
Via Chartmill
Which stocks are moving on Thursday?
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
These stocks are gapping in today's session
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
Tandem Diabetes Crashes 32% As Light Outlook Rattles Pump-Maker's Shares
Shares hit their lowest point since January 2024 after the stock market opened Thursday. 
Via Investor's Business Daily
Get insights into the top gainers and losers of Thursday's pre-market session.
Wondering what's happening in Thursday's pre-market session? Find an overview in this article. 
Via Chartmill
These stocks are moving in today's after hours session
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
Tandem Diabetes’s (NASDAQ:TNDM) Q4 Sales Beat Estimates But Stock Drops 12.2%
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 35% year on year to $282.6 million. The company expects next quarter’s... 
Via StockStory
Topics Earnings
Exposures Financial
Tandem Diabetes (TNDM) Q4 Earnings: What To Expect
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) will be reporting earnings tomorrow after the bell. Here’s what to expect. 
Via StockStory
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges. 
Via Benzinga
This MINISO Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says
RBC Capital Markets initiates coverage on Tandem Diabetes Care (TNDM) with an Outperform rating and $65 price target, citing growth opportunities in the U.S. Type 1 and Type 2 diabetes markets, product... 
Via Benzinga
Why Tandem Diabetes Care Stock Took It on the Chin Tuesday
Flat revenue growth might be in store for the company in a very crucial market. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.